Join ESGO President Nicole Concin, Christina Fotopoulou, Xavier Matias-Guiu and Carien Creutzberg with Jonathan Berek for a @FIGOHQ webinar on the updated 2023 FIGO #endometrialcancer staging system
📆 Aug 24 16h
🗣️: 🇬🇧 discussion with live interpretation to 🇫🇷 & 🇪🇸
Register 👉 https://t.co/9E5TLCiZKg
FIGO and IJGO recently published the FIGO Staging of Endometrial Cancer: 2023. This update incorporates new evidence and improves understanding of endometrial cancers' complex nature to allow for better-adapted treatment. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding thr new subclassifications to the proposed molecular and histological FIGO staging system.
We look forward to the webinar!
#oncoalert
NOT a good step in the right direction! Sorry but NOT the best moment for @FIGO Let’s make the staging as confusing as possible and as impractical as possible for low and middle income countries!#EndometrialCancer@IGCSociety@ESGO_society@IGCSociety@SGO_org
SHAPE Trial is here!!
♦️<2cm and <50% stromal invasion
♦️Simple hyst vs radical
♦️No differences in survival (3-year ERFS and OS 98.1% and 99.1% with SH; 99.7% and 99.4% with RH)
♦️Better QoL and lower morbidity with SH
♦️75% of the patiens operated by MIS
🫨🫨🫨🫨
@ASCO
@sunangelae@RParejaGineOnco@sogvzlaoficial@AndreFernandes2@oncohoegl Cierto... Dra Sunsangela, grato contar con conocimientos frescos, innovadores y lo más importante... Desinteresados... de todos ustedes... Viva la academia y humildemente estoy a sus órdenes, se vienen mejores cosas